Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Biotech firms Redx Pharma and Jounce Therapeutics to merge in $425 million deal

Published 23/02/2023, 07:33
Updated 23/02/2023, 15:42
© Reuters.

(Reuters) -British biotech firm Redx Pharma plc and U.S.-based Jounce Therapeutics Inc will merge to create a $425 million entity specialised in treating cancer and fibrotic disease.

Redx shareholders will receive 0.2105 Jounce share in exchange for each Redx share, the companies said on Thursday, adding that the combined company would be called Redx Inc and will be listed on Nasdaq.

Redx shareholders will own about 63%, while Jounce shareholders will own 37% of the combined group, the statement added.

Jounce said it intends to conduct a reverse stock split of its shares in line with the combination, with a ratio of one new share for every five outstanding stocks of Jounce.

The all-share merger is expected to be completed by the second quarter.

The new company will be led by Redx CEO Lisa Anson and will be headquartered in the UK, with a drug discovery and clinical development team in the United States, the companies said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.